 Acadia Pharmaceuticals Inc. ACAD, 3.94 said Friday its stock will be halted from trading Friday as a U.S. Food and Drug Administration panel meets virtually to discuss a new drug application for a treatment for hallucinations and delusions associated with Alzheimers disease psychosis. The FDAs Psychopharmacologic Drugs Advisory Committee will review Acadias Nuplazid at a meeting scheduled for 8:45 a.m. 